S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
This phase II trial is study how well AZD2171 works in treating patients with malignant pleural mesothelioma that cannot be removed by surgery. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jan 23, 2018 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- National Cancer Institute (NCI)
- Interventions being studied
- Drug: cediranib maleate; Other: laboratory biomarker analysis
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Histologically confirmed epithelial, sarcomatous, or biphasic malignant pleural mesothelioma
- Unresectable disease
- Residual disease after prior cytoreductive surgery allowed
- Measurable disease by CT scan or MRI
- Prior treatment with platinum-based chemotherapy required
- No known CNS metastasis
- Performance status
- Zubrod 0-2
- WBC \>= 3,000/mm\^3
- Absolute neutrophil count \>= 1,500/mm\^3
- Platelet count \>= 100,000/mm\^3
- AST or ALT =\< 1.5 times upper limit of normal (ULN)
- Bilirubin normal
- Creatinine =\< 1.5 times ULN OR
- Creatinine clearance \>= 50 mL/min
- Proteinuria =\< 1+ by 2 consecutive dipstick tests taken \>= 1 week apart
- No history of familial long QT syndrome
- Mean QTc =\< 470 msec
- Systolic BP =\< 150 mm Hg AND diastolic BP =\< 100 mm Hg
- Must have New York Heart Association class I or II disease
- Class II must be controlled with treatment
- Able to swallow and/or receive enteral medications via gastrostomy feeding tube
- Not requiring IV alimentation
- No active peptic ulcer
- No intractable nausea or vomiting
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in remission
- No history of hypersensitivity reaction to compounds of similar chemical or biological composition to the study drug
- Prior monoclonal antibody therapy targeting vascular endothelial growth factor (VEGF), VEGF receptor 1(VEGFR1) or VEGF receptor 2 (VEGFR2) allowed
- No other prior immunotherapy or biologic therapy
- No prior thymidine kinase inhibitor against VEGFR1 or VEGFR2
- No concurrent drugs or biologics with proarrhythmic potential
- No more than 1 prior chemotherapy regimen
- At least 28 days since prior chemotherapy (42 days for nitrosoureas or mitomycin) and recovered
- At least 21 days since prior radiotherapy and recovered
- At least 28 days since prior major surgery (e.g., thoracotomy or laparotomy) and recovered
- No prior surgery that would affect absorption
- Stable antihypertensive therapy allowed provided blood pressure (BP) parameters are met
- Concurrent enrollment on SWOG-S9925 allowed
- No concurrent combination antiretroviral therapy for HIV-positive patients
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Southwest Oncology GroupSan Antonio, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 23, 2018. Always confirm current availability with the study team.